Antibodies are challenged

Indian Journal of Medical Sciences

Volumn 64, Issue 3, 2010, Pages 144-147

  Banerjee, Jayeeta ^a  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

Antibody; antibody vs aptamer; aptamer; SELEX

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; APTAMER; AS 1411; OLIGONUCLEOTIDE; PEGAPTANIB; PEPTIDE APTAMER; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ARTICLE; BINDING AFFINITY; COMBINATORIAL CHEMISTRY; DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MARKETING; GENE EXPRESSION; HUMAN; NONHUMAN; NUCLEOTIDE METABOLISM; PEPTIDE SYNTHESIS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN FOLDING; RETINA MACULA AGE RELATED DEGENERATION;

ANTIBODIES; APTAMERS, NUCLEOTIDE; APTAMERS, PEPTIDE; HUMANS;

EID: 84862081875     PISSN: 00195359     EISSN: 19983654     Source Type: Journal    
DOI: 10.4103/0019-5359.95928     Document Type: Article

References (5)

1. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007;14:283-91. (Pubitemid 46231922)
2. Reyes-Reyes E, Teng Y, Bates P. A new paradigm for aptamer therapeutic AS1411 action: Uptake by macro pinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res 2010;70:8617-29.
3. BCC research data from Lucerna 2010.
4. Blind M, Kolanus W, Famulok M. Cytoplasmic RNA modulators of an inside-out signaltransduction cascade. Proc Natl Acad Sci USA 1999;96:3606-10. (Pubitemid 29168957)
5. Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, Heidel JD, et al. Development of universal antidotes to control aptamer activity. Nat Med 2009;15:1224-8.